SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (392)8/14/2001 1:27:33 PM
From: Extra Pale  Read Replies (1) of 438
 
GZMO IR response to my query for comments related to article alleging improper procedures in Kugler Kidney cancer trial (see gzmo post #392)

Regarding the article, we have no comment regarding the article
specifically. These were not our studies although we have talked to the
groups involved as well as with others involved in fusion work.

We are working with Dr. Kufe at the Dana Farber here in Boston who pioneered
the fusion technology. We have three trials underway with a chemical fusion
process, and we plan to start two trials with the electrofusion process
(similar to that used by Dr. Kugler) later this year. Our goal is to
compare the two approaches to making fusions. As with any novel approach,
we believe it is important to have reproducible results in multiple centers
and multiple trials. We are also conducting preclinical studies in our labs
and sponsoring work at BruCells in Belgium to analyze and optimize the
process for making fusions.

I hope this clarifies our program.

Regards,
Kristen Nally
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News